$XBI $128.29 -1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA -3% Supply agreement with Israel for 2022. source
$SRNE -1% Announces ph 1 results of COVI-MSC in ICU Covid-19 patients. source
Pipeline Updates
$ALKS +1% New exploratory analysis from ph 3 study presented. source
$EVLO -5% Updates ph 1 data presented. source
$YMAB +3% update on Type B meeting with FDA, maintain timeline of Q2/Q3 for BLA resubmission. source
$CRBP +2% Ph 2 enrollment completed, results expected H2 2021. source
$BLUE -1% Withdraws Zynteglo from German market after pricing negotiations, LentiGlobin SAE determined to be transfusion-dependent anemia not MDS. source
$SNDX -28% Presents updates ph 1/2 data from AUGMENT-101 study. Ph 2 to initiated by end of quarter. source
$CYCN +7% Will host pipeline update and KOL call on 4/27/21. source
$SEEL +2% Positive EMA opinion on Orphan Drug Designation for SLS-005 for ALS. source
$GWPH -1% EU approval of Epidyolex for TSC. source
$KALV +3% Ph 2 study put on clinical hold by FDA, requiring more information and analysis from preclinical studies. No new studies requested. source
$ERYP +1% Requested pre-BLA meeting for eryapase fo hypersensitive ALL patients, with BLA submission expected H2 2021. source
Finance Updates
$LCTX 0% WW licensing and dev agreement with Immunomic for novel product candidate. source
Comments